secwatch.observer — SEC 8-K summary
======================================

Issuer:     ALNYLAM PHARMACEUTICALS, INC. (ALNY)
CIK:        0001178670
Form:       8-K
Filed at:   2023-11-02T23:59:59+00:00
Accession:  0001157523-23-001622
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alnylam Q3 2023 net product revenues $313M (+35% YoY); FDA CRL for ONPATTRO cardiomyopathy
--------------------------------------------------------------------------------

- Q3 net product revs $313M (+35% YoY); GAAP net income $147.8M ($1.15 diluted EPS) vs loss of $405.9M in Q3 2022.
- FDA issued Complete Response Letter for patisiran (ONPATTRO) sNDA for ATTR cardiomyopathy.
- Positive topline results from KARDIA-1 Phase 2 study of zilebesiran in hypertension; entered global collaboration with Roche.
- Updated 2023 guidance: collaboration & royalty rev $575-625M; net product rev reiterated at $1,200-1,285M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178670/000115752323001622/0001157523-23-001622-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178670/000115752323001622/a53737945.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001622

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer